Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner
- PMID: 15289312
- DOI: 10.1158/0008-5472.CAN-03-2214
Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner
Abstract
We have shown previously that the molecular chaperone heat shock protein 90 (Hsp90) is required for a proper centrosome function. Indeed, this Hsp90 function seems to be reflected in Polo-like kinase stability. Inhibition of Hsp90 in HeLa cells results in cell cycle arrest either in G2 stage or at the metaphase-anaphase transition. Here, we show that this inhibition leads to inactivation of the anaphase-promoting complex or cyclosome by both dephosphorylation and induction of the spindle assembly checkpoint. Hsp90 inhibition compromises two of the main mitotic kinases, Polo-like kinase 1 (Plk1) and cdc2. Interestingly, this mitotic arrest does not occur in certain tumor cell lines where Hsp90 and Plk1 are not associated. Those cells are able to process mitosis successfully and have an active Plk1 despite Hsp90 inactivation. Therefore, it seems that Hsp90 regulates completion of mitosis depending on its association with Plk1.
Similar articles
-
Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1.Nat Cell Biol. 2007 Apr;9(4):436-44. doi: 10.1038/ncb1557. Epub 2007 Mar 11. Nat Cell Biol. 2007. PMID: 17351640
-
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.Clin Cancer Res. 2006 Jan 15;12(2):584-90. doi: 10.1158/1078-0432.CCR-05-1194. Clin Cancer Res. 2006. PMID: 16428504
-
Complex formation of Plk1 and INCENP required for metaphase-anaphase transition.Nat Cell Biol. 2006 Feb;8(2):180-7. doi: 10.1038/ncb1350. Epub 2005 Dec 25. Nat Cell Biol. 2006. PMID: 16378098
-
Getting in and out of mitosis with Polo-like kinase-1.Oncogene. 2005 Apr 18;24(17):2844-59. doi: 10.1038/sj.onc.1208617. Oncogene. 2005. PMID: 15838519 Review.
-
Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis.Cancer Res. 2006 Jul 15;66(14):6895-8. doi: 10.1158/0008-5472.CAN-06-0358. Cancer Res. 2006. PMID: 16849530 Review.
Cited by
-
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.Invest New Drugs. 2012 Dec;30(6):2201-9. doi: 10.1007/s10637-011-9790-6. Epub 2012 Jan 10. Invest New Drugs. 2012. PMID: 22227828 Free PMC article.
-
Induction of premature senescence by hsp90 inhibition in small cell lung cancer.PLoS One. 2010 Jun 11;5(6):e11076. doi: 10.1371/journal.pone.0011076. PLoS One. 2010. PMID: 20552022 Free PMC article.
-
Natural product Celastrol destabilizes tubulin heterodimer and facilitates mitotic cell death triggered by microtubule-targeting anti-cancer drugs.PLoS One. 2010 Apr 23;5(4):e10318. doi: 10.1371/journal.pone.0010318. PLoS One. 2010. PMID: 20428237 Free PMC article.
-
The Hsp90 inhibitor geldanamycin abrogates colocalization of eIF4E and eIF4E-transporter into stress granules and association of eIF4E with eIF4G.J Biol Chem. 2009 Dec 18;284(51):35597-604. doi: 10.1074/jbc.M109.036285. J Biol Chem. 2009. PMID: 19850929 Free PMC article.
-
Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.Mol Cancer Ther. 2016 Sep;15(9):2107-18. doi: 10.1158/1535-7163.MCT-16-0241. Epub 2016 Jul 7. Mol Cancer Ther. 2016. PMID: 27390342 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous